Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7081274 | 0.84 | LMNA (0.51) | LMNAKDM4ESMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL7077256 | 0.83 | LMNA (0.51) | LMNAKDM4ESMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL7081932 | 0.81 | LMNA (0.49) | LMNAKDM4ESMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL7077332 | 0.81 | LMNA (0.48) | LMNAKDM4ESMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL7163459 | 0.80 | TSHR (0.43) | LMNAKDM4ESMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL7081641 | 0.80 | LMNA (0.47) | LMNAKDM4ESMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL7081942 | 0.79 | LMNA (0.46) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL7083098 | 0.79 | LMNA (0.47) | LMNAKDM4ESMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL7002562 | 0.77 | KDM4E (0.53) | LMNAKDM4ESMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL7000049 | 0.75 | SMN1; SMN2 (0.44) | LMNAKDM4ESMN1; SMN2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186997-A1 | 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same | ELBION AG (DE) | 2003-10-02 | — | — | US | claimed |
| US-20030186997-A1 | 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same | ELBION AG (DE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186997-A1 | 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same | DDO, GRIN3A, GRIK4 | LMNA 1746/4885KDM4E 1874/4885SMN1; SMN2 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.